New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences

More documents

Recommendations

Info

2 nd Annual Essentials in Primary Care Fall Conference Friday, November 11, 2011 Rivaroxaban - Xarelto • Patients with any degree of renal impairment with concurrent use of P-gp and weak to moderate CYP3A4 inhibitors may have significant increases in exposure which may increase bleeding risk • Avoid concomitant use of rivaroxaban with drugs that are combined P-gp and strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John’s wort). Consider increasing the rivaroxaban dose if these drugs must be co-administered Rivaroxaban - Xarelto • Avoid the use of rivaroxaban in patients with severe renal impairment (CrCl
2 nd Annual Essentials in Primary Care Fall Conference Friday, November 11, 2011 Rivaroxaban - Xarelto Rivaroxaban - Xarelto Wayne Weart New Drug Update Part I
Page 1 and 2: 2 nd Annual Essentials in Primary C
Page 35: 2 nd Annual Essentials in Primary C
Page 77: 2 nd Annual Essentials in Primary C

New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?